No Data
Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), Molina Healthcare (MOH) and Edwards Lifesciences (EW)
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's Is How to Trade
Press Release: Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
No Data
No Data
